You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CPD

Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia: Data, Application, and Patient Selection

  • Authors: John Gribben, MD, DSc, FMedSci
  • CPD Released: 9/7/2022
  • Valid for credit through: 9/7/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 1.00 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematology/oncology specialists, pathologists, and cardiologists.

The goal of this activity is that learners will be better able to improve physician knowledge, competence, and confidence regarding the available clinical data and application of BTK inhibitors for patients with CLL.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Key mechanistic differences between first- and next-generation BTK inhibitors
    • Available clinical data on BTK inhibitors for CLL
    • Different side effect profiles of BTK inhibitors for CLL
  • Have greater competence related to
    • Managing patients with CLL with BTK inhibitors
  • Demonstrate greater confidence in their ability to
    • Understand where next-generation BTK inhibitors fit in the treatment algorithm for CLL


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.

Disclosures for additional planners can be found here.


Faculty

  • John Gribben, MD, DSc, FMedSci

    Hamilton Fairley Chair of Medical Oncology
    Centre Lead, Centre for Haemato-Oncology
    Barts Cancer Institute
    Queen Mary University of London
    London, United Kingdom

    Disclosures

    John Gribben, MD, DSc, FMedSci, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; AstraZeneca; TG Therapeutics
    Speaker or member of speakers bureau for: AbbVie; Bristol Myers Squibb; Gilead; Janssen; Kite
    Research funding from: AstraZeneca; Celgene; Janssen

Editors

  • Keisha Peters, MSc

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Keisha Peters, MSc, has no relevant financial relationships.

  • Lisa Cockrell, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    Lisa Cockrell, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.0 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia: Data, Application, and Patient Selection

Authors: John Gribben, MD, DSc, FMedSciFaculty and Disclosures

CPD Released: 9/7/2022

Valid for credit through: 9/7/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to improve physician knowledge, competence, and confidence regarding the available clinical data and application of Bruton tyrosine kinase (BTK) inhibitors for patients with chronic lymphocytic leukemia (CLL).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print